Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial

Determining targets for antiretroviral drug concentrations: a causal framework illustrated with pediatric efavirenz data from the CHAPAS-3 trial

<p><strong>Background: </strong>Determining a therapeutic window for maintaining antiretroviral drug concentrations within an appropriate range is required for identifying effective dosing regimens. The limits of this window are typically calculated using predictive models...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Schomaker, M, Denti, P, Bienczak, A, Burger, D, Díaz, I, Gibb, DM, Walker, AS, McIlleron, H
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	Wiley 2024

Gelijkaardige items

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
door: Bienczak, A, et al.
Gepubliceerd in: (2016)

Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.
door: Bienczak, A, et al.
Gepubliceerd in: (2016)

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource‐limited settings
door: Alemseged Abdissa, et al.
Gepubliceerd in: (2014-01-01)

Pharmacokinetics of antiretroviral drugs in infancy
door: Helen McIlleron, et al.
Gepubliceerd in: (2009-12-01)

Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets
door: Bienczak, A, et al.
Gepubliceerd in: (2017)

Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
door: Fillekes, Q, et al.
Gepubliceerd in: (2011)

The effect of diurnal variation, CYP2B6 genotype, and age on the pharmacokinetics of nevirapine in African Children
door: Bienczak, A, et al.
Gepubliceerd in: (2016)

Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania
door: Selemani Saidi Sungi, et al.
Gepubliceerd in: (2018-10-01)

Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz
door: Larru B, et al.
Gepubliceerd in: (2014-05-01)

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
door: Mulenga, V, et al.
Gepubliceerd in: (2016)

Virologic response to first-line efavirenz- or nevirapine-based antiretroviral therapy in HIV-infected African children
door: Kekitiinwa, A, et al.
Gepubliceerd in: (2017)

Getting drug doses right in children with tuberculosis (TB)
door: H. McIlleron
Gepubliceerd in: (2014-04-01)

‘Covering the tail’ after stopping efavirenz-based antiretroviral therapy
door: Gary Maartens
Gepubliceerd in: (2020-01-01)

Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
door: Musiime, V, et al.
Gepubliceerd in: (2014)

Acute Liver Failure among Patients on Efavirenz-Based Antiretroviral Therapy
door: Innocent Lule Segamwenge, et al.
Gepubliceerd in: (2018-01-01)

Drug resistance after cessation of efavirenz-based antiretroviral treatment started in pregnancy
door: Globahan Ajibola, et al.
Gepubliceerd in: (2020-01-01)

Lopinavir/r + Efavirenz combination as a potent NRTI sparing antiretroviral therapy
door: Vandercam Bernard, et al.
Gepubliceerd in: (2010-05-01)

Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
door: Oudijk, J, et al.
Gepubliceerd in: (2012)

Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir based antiretroviral therapy
door: Dorward, J, et al.
Gepubliceerd in: (2023)

A model-based approach for a practical dosing strategy for the short, intensive treatment regimen for paediatric tuberculous meningitis
door: Roeland E. Wasmann, et al.
Gepubliceerd in: (2023-04-01)

Antiretroviral drugs efavirenz, dolutegravir and bictegravir dysregulate blood-brain barrier integrity and function
door: Chang Huang, et al.
Gepubliceerd in: (2023-03-01)

Kinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.
door: Jan Vesterbacka, et al.
Gepubliceerd in: (2013-01-01)

Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis
door: Richard Court, et al.
Gepubliceerd in: (2021-04-01)

Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission.
door: Patience Nyakato, et al.
Gepubliceerd in: (2020-01-01)

Combination of Antiretroviral Drugs Zidovudine and Efavirenz Impairs Tumor Growths in a Mouse Model of Cancer
door: Marcel A. Schneider, et al.
Gepubliceerd in: (2021-11-01)

Efavirenz in pregnancy
door: Polly Clayden, et al.
Gepubliceerd in: (2010-11-01)

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
door: Lufina Tsirizani Galileya, et al.
Gepubliceerd in: (2023-11-01)

Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis
door: Lufina Tsirizani Galileya, et al.
Gepubliceerd in: (2023-11-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
door: Tarcyla Andrade Gomes, et al.
Gepubliceerd in: (2015-04-01)

Estratégias utilizadas para o incremento da solubilidade do fármaco antiretroviral classe II: Efavirenz
door: Tarcyla Andrade Gomes, et al.
Gepubliceerd in: (2015-10-01)

Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda
door: Adelline Twimukye, et al.
Gepubliceerd in: (2021-11-01)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
door: Sanjeev Sinha, et al.
Gepubliceerd in: (2017-12-01)

Correlation of hair and plasma efavirenz concentrations in HIV-positive South Africans
door: Jenna Johnston, et al.
Gepubliceerd in: (2019-04-01)

Efavirenz-induced urolithiasis.
door: Wirth, G, et al.
Gepubliceerd in: (2006)

Efavirenz and neuropsychiatric effects
door: Mukesh Dheda
Gepubliceerd in: (2017-04-01)

Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study
door: Sinxadi Phumla Z, et al.
Gepubliceerd in: (2012-10-01)

Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens
door: Gabriella Jomara da Silva, et al.
Gepubliceerd in: (2023-05-01)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
door: Rebecca Zash, MD, et al.
Gepubliceerd in: (2018-07-01)

Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil
door: T. Vanni, et al.
Gepubliceerd in: (2007-07-01)

Gynecomastia in HIV-positive adult men receiving efavirenz-based antiretroviral therapy at Newlands clinic, Harare, Zimbabwe
door: Sandra Shawarira-Bote, et al.
Gepubliceerd in: (2019-08-01)